Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent

Human Gene Therapy

Volumn 13, Issue 10, 2002, Pages 1225-1233

  King, Ivan ^a   Lang, Wenshang ^a   Runyan, Jacob D ^a   Luo, Xiang ^a   Li, Zujin ^a   Zheng, Li Mou ^a   Bermudes, David ^a   Lin, Stanley ^a   Belcourt, Michael ^a   Pike, Jeremy ^a   Troy, Kimberly ^a   Le, Trung ^a   Ittensohn, Martina ^a   Mao, John ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; DEAMINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ESCHERICHIA COLI; FEMALE; GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; ANIMAL; ANTIBODY SPECIFICITY; BIOTRANSFORMATION; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; ENZYMOLOGY; GENETIC MARKER; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; COLONIC NEOPLASMS; ESCHERICHIA COLI; FEMALE; FLUCYTOSINE; FLUOROURACIL; GENETIC MARKERS; HUMAN; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; ORGAN SPECIFICITY; SALMONELLA TYPHIMURIUM; TUMOR CELLS, CULTURED; ANIMALS; CYTOSINE DEAMINASE; HUMANS;

ANIMALIA; ESCHERICHIA COLI; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 0036019203     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402320139005     Document Type: Article

References (22)

1. 5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur
2. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium
3. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001
4. Genetic delivery of enzymes for cancer therapy
5. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
6. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
7. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts
8. Human cytidine deaminase: Purification of enzyme, cloning, and expression of its complementary DNA
9. Comparative toxicological evaluation in monkeys, pigs, and mice, of a genetically-engineered Salmonella (VNP20009) being developed as an anti-tumor agent
10. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent
11. Tumor-directed delivery and amplification of tumor-necrosis factor-a (TNF-a) by attenuated Salmonella typhimurium
12. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors
13. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo
14. Anti-tumor effect of VNP20009, an attenuated Salmonella, in murine tumor models
15. Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: A study in breast cancer patients
16. Tumor-targeted Salmonella as a novel anticancer vector
17. Association of intratumoral pharmacokinetics of fluorouracil with clinical response
18. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent
19. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: A novel anti-tumor agent
20. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma
21. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium
22. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector